{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:28:48Z","timestamp":1792639728814,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,21]],"date-time":"2014-09-21T00:00:00Z","timestamp":1411257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s11910-014-0500-6","type":"journal-article","created":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T02:47:59Z","timestamp":1411181279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["Tau PET Imaging in Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"14","author":[{"given":"Nobuyuki","family":"Okamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Furumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitsuka","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,21]]},"reference":[{"key":"500_CR1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science."},{"key":"500_CR2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"500_CR3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron M. Alzheimer\u2019s disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387\u201398.","journal-title":"Nat Rev Drug Discov"},{"key":"500_CR4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","volume":"9","author":"E Giacobini","year":"2013","unstructured":"Giacobini E, Gold G. Alzheimer disease therapy\u2013moving from amyloid-beta to tau. Nat Rev Neurol. 2013;9:677\u201386.","journal-title":"Nat Rev Neurol"},{"key":"500_CR5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","volume":"8","author":"C Ballatore","year":"2007","unstructured":"Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat Rev Neurosci. 2007;8:663\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"500_CR6","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"500_CR7","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","volume":"261","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084\u20139.","journal-title":"J Biol Chem"},{"key":"500_CR8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0197-4580(91)90006-6","volume":"12","author":"JL Price","year":"1991","unstructured":"Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer\u2019s disease. Neurobiol Aging. 1991;12:295\u2013312.","journal-title":"Neurobiol Aging"},{"key":"500_CR9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351\u20137.","journal-title":"Neurobiol Aging"},{"key":"500_CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"500_CR11","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","volume":"52","author":"A Delacourte","year":"1999","unstructured":"Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer\u2019s disease. Neurology. 1999;52:1158\u201365.","journal-title":"Neurology"},{"key":"500_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/archneur.1995.00540250089017","volume":"52","author":"LM Bierer","year":"1995","unstructured":"Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer\u2019s disease. Arch Neurol. 1995;52:81\u20138.","journal-title":"Arch Neurol"},{"key":"500_CR13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","volume":"42","author":"PV Arriagada","year":"1992","unstructured":"Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology. 1992;42:631\u20139.","journal-title":"Neurology"},{"key":"500_CR14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrneurol.2009.217","volume":"6","author":"A Nordberg","year":"2010","unstructured":"Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6:78\u201387.","journal-title":"Nat Rev Neurol"},{"key":"500_CR15","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/j.jalz.2014.04.013","volume":"10","author":"VL Villemagne","year":"2014","unstructured":"Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheimers Dement. 2014;10:S254\u201364.","journal-title":"Alzheimers Dement"},{"key":"500_CR16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/fnl.12.34","volume":"7","author":"VL Villemagne","year":"2012","unstructured":"Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Harada R, Mulligan RS, Kudo Y, et al. The challenges of tau imaging. Futur Neurol. 2012;7:409\u201321.","journal-title":"Futur Neurol"},{"key":"500_CR17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.113.136069","volume":"55","author":"M Shah","year":"2014","unstructured":"Shah M, Catafau AM. Molecular Imaging Insights into neurodegeneration: focus on Tau PET Radiotracers. J Nucl Med. 2014;55:871\u20134.","journal-title":"J Nucl Med"},{"key":"500_CR18","doi-asserted-by":"crossref","unstructured":"Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365\u201371.","DOI":"10.1523\/JNEUROSCI.0630-07.2007"},{"key":"500_CR19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","volume":"617","author":"MT Fodero-Tavoletti","year":"2009","unstructured":"Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, et al. In vitro characterisation of BF227 binding to alpha-synuclein\/Lewy bodies. Eur J Pharmacol. 2009;617:54\u20138.","journal-title":"Eur J Pharmacol"},{"key":"500_CR20","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/brain\/awt142","volume":"136","author":"R Ni","year":"2013","unstructured":"Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer\u2019s disease brain tissue. Brain. 2013;136:2217\u201327.","journal-title":"Brain"},{"key":"500_CR21","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","volume":"50","author":"SR Choi","year":"2009","unstructured":"Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18 F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50:1887\u201394.","journal-title":"J Nucl Med"},{"key":"500_CR22","doi-asserted-by":"crossref","unstructured":"Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4\u2032-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23:2086\u201392.","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003"},{"key":"500_CR23","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","volume":"46","author":"CA Mathis","year":"2003","unstructured":"Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740\u201354.","journal-title":"J Med Chem"},{"key":"500_CR24","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.neuroimage.2012.01.066","volume":"60","author":"KN Schafer","year":"2012","unstructured":"Schafer KN, Kim S, Matzavinos A, Kuret J. Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer\u2019s disease: a simulation study. Neuroimage. 2012;60:1724\u201333.","journal-title":"Neuroimage"},{"key":"500_CR25","unstructured":"Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18 F-AV-45: a PET agent for Abeta plaques in the brain. J Neurosci. 2009;50:1887\u201394."},{"key":"500_CR26","doi-asserted-by":"crossref","unstructured":"Snellman A, Rokka J, Lopez-Picon FR, Eskola O, Wilson I, Farrar G, et al. Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2012;39:1784\u201395.","DOI":"10.1007\/s00259-012-2178-9"},{"key":"500_CR27","first-page":"1030","volume":"24","author":"DD Dischino","year":"1983","unstructured":"Dischino DD, Welch MJ, Kilbourn MR, Raichle ME. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med. 1983;24:1030\u20138.","journal-title":"J Nucl Med"},{"key":"500_CR28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1474-4422(11)70123-5","volume":"10","author":"K Herholz","year":"2011","unstructured":"Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer\u2019s disease. Lancet Neurol. 2011;10:667\u201370.","journal-title":"Lancet Neurol"},{"key":"500_CR29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","volume":"10","author":"K Shoghi-Jadid","year":"2002","unstructured":"Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatr. 2002;10:24\u201335.","journal-title":"Am J Geriatr Psychiatr"},{"key":"500_CR30","doi-asserted-by":"crossref","first-page":"RC189","DOI":"10.1523\/JNEUROSCI.21-24-j0004.2001","volume":"21","author":"ED Agdeppa","year":"2001","unstructured":"Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer\u2019s disease. J Neurosci. 2001;21:RC189.","journal-title":"J Neurosci"},{"key":"500_CR31","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","volume":"355","author":"GW Small","year":"2006","unstructured":"Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652\u201363.","journal-title":"N Engl J Med"},{"key":"500_CR32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neuroimage.2008.07.022","volume":"43","author":"J Shin","year":"2008","unstructured":"Shin J, Lee SY, Kim SH, Kim YB, Cho SJ. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer\u2019s disease. Neuroimage. 2008;43:236\u201344.","journal-title":"Neuroimage"},{"key":"500_CR33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jagp.2012.11.019","volume":"21","author":"GW Small","year":"2013","unstructured":"Small GW, Kepe V, Siddarth P, Ercoli LM, Merrill DA, Donoghue N, et al. PET scanning of brain tau in retired national football league players: preliminary findings. Am J Geriatr Psychiatr. 2013;21:138\u201344.","journal-title":"Am J Geriatr Psychiatr"},{"key":"500_CR34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrneurol.2013.36","volume":"9","author":"ST DeKosky","year":"2013","unstructured":"DeKosky ST, Blennow K, Ikonomovic MD, Gandy S. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol. 2013;9:192\u2013200.","journal-title":"Nat Rev Neurol"},{"key":"500_CR35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-130032","volume":"36","author":"V Kepe","year":"2013","unstructured":"Kepe V, Bordelon Y, Boxer A, Huang SC, Liu J, Thiede FC, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis. 2013;36:145\u201353.","journal-title":"J Alzheimers Dis"},{"key":"500_CR36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","volume":"79","author":"M Maruyama","year":"2013","unstructured":"Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094\u2013108. Maruyama et al. performed first-in-man PET studies of [ 11 C]PBB3 in 3 healthy controls and 3 AD patients. [ 11 C]PBB3 retention was observed in the hippocampus of AD patients, suggesting that this tracer binds to NFTs in vivo. In addition, [ 11 C]PBB3 binding to tau deposits was reported in the basal ganglia of CBD patient.","journal-title":"Neuron"},{"key":"500_CR37","doi-asserted-by":"crossref","unstructured":"Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, et al. Radiosynthesis, Photoisomerization, Biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of Tau pathology. J Nucl Med. 2014;55:1532-8.","DOI":"10.2967\/jnumed.114.139550"},{"key":"500_CR38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JAD-122059","volume":"34","author":"DT Chien","year":"2013","unstructured":"Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457\u201368. The first-in-man PET studies of [ 18 F]T807 demonstrated significant tracer retention in the frequent areas of PHF-tau in AD brain. [ 18 F]T807 retention was associated with increasing disease severity. In addition, [ 18 F]T807 shows very low non-specific binding of the tracer in the white matter.","journal-title":"J Alzheimers Dis"},{"key":"500_CR39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-130098","volume":"38","author":"DT Chien","year":"2014","unstructured":"Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu FR, Xia CF, et al. Early clinical PET imaging results with the Novel PHF-Tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171\u201384.","journal-title":"J Alzheimers Dis"},{"key":"500_CR40","doi-asserted-by":"crossref","unstructured":"Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimers Dement. 2013.","DOI":"10.1016\/j.jalz.2012.11.008"},{"key":"500_CR41","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1523\/JNEUROSCI.1738-05.2005","volume":"25","author":"N Okamura","year":"2005","unstructured":"Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer\u2019s disease. J Neurosci. 2005;25:10857\u201362.","journal-title":"J Neurosci"},{"key":"500_CR42","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awr038","volume":"134","author":"MT Fodero-Tavoletti","year":"2011","unstructured":"Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, et al. 18 F-THK523: a novel in vivo tau imaging ligand for Alzheimer\u2019s disease. Brain. 2011;134:1089\u2013100.","journal-title":"Brain"},{"key":"500_CR43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00259-012-2261-2","volume":"40","author":"R Harada","year":"2013","unstructured":"Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, et al. Comparison of the binding characteristics of [18 F]THK-523 and other amyloid imaging tracers to Alzheimer\u2019s disease pathology. Eur J Nucl Med Mol Imaging. 2013;40:125\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"500_CR44","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","volume":"54","author":"N Okamura","year":"2013","unstructured":"Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18 F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420\u20137.","journal-title":"J Nucl Med"},{"key":"500_CR45","doi-asserted-by":"crossref","unstructured":"Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:816-26.","DOI":"10.1007\/s00259-013-2681-7"},{"key":"500_CR46","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/brain\/awu064","volume":"137","author":"N Okamura","year":"2014","unstructured":"Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer\u2019s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137:1762\u201371. The first-in man studies of [ 18 F]THK-5105 demonstrated tracer retention in the frequent areas of PHF-tau in AD brain. Tracer retention was associated with clinical severity of dementia and brain atrophy, which is consistent with the observation of postmortem studies.","journal-title":"Brain"},{"key":"500_CR47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/alzrt240","volume":"6","author":"MT Fodero-Tavoletti","year":"2014","unstructured":"Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, Mulligan RS, Birchall I, et al. Assessing THK523 selectivity for tau deposits in Alzheimer\u2019s disease and non Alzheimer\u2019s disease tauopathies. Alzheimers Res Ther. 2014;6:11.","journal-title":"Alzheimers Res Ther"},{"key":"500_CR48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/alzrt234","volume":"6","author":"TD Stein","year":"2014","unstructured":"Stein TD, Alvarez VE, McKee AC. Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Res Ther. 2014;6:4.","journal-title":"Alzheimers Res Ther"},{"key":"500_CR49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/brain\/aws307","volume":"136","author":"AC McKee","year":"2013","unstructured":"McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136:43\u201364.","journal-title":"Brain"},{"key":"500_CR50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000051245","volume":"12","author":"M Yamada","year":"2001","unstructured":"Yamada M, Itoh Y, Sodeyama N, Suematsu N, Otomo E, Matsushita M, et al. Senile dementia of the neurofibrillary tangle type: a comparison with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2001;12:117\u201326.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"500_CR51","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jnen\/63.9.911","volume":"63","author":"Y Saito","year":"2004","unstructured":"Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol. 2004;63:911\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"key":"500_CR52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000341577","volume":"34","author":"J Takeuchi","year":"2012","unstructured":"Takeuchi J, Shimada H, Ataka S, Kawabe J, Mori H, Mizuno K, et al. Clinical features of Pittsburgh compound-B-negative dementia. Dement Geriatr Cogn Disord. 2012;34:112\u201320.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"500_CR53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","volume":"71","author":"CR Jack Jr","year":"2012","unstructured":"Jack Jr CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer\u2019s association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765\u201375.","journal-title":"Ann Neurol"},{"key":"500_CR54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/JMN:17:2:101","volume":"17","author":"JC Morris","year":"2001","unstructured":"Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer\u2019s disease. J Mol Neurosci. 2001;17:101\u201318.","journal-title":"J Mol Neurosci"},{"key":"500_CR55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack Jr CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol"},{"key":"500_CR56","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature08538","volume":"461","author":"RJ Perrin","year":"2009","unstructured":"Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer\u2019s disease. Nature. 2009;461:916\u201322.","journal-title":"Nature"},{"key":"500_CR57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1155\/2009\/609839","volume":"21","author":"GD Rabinovici","year":"2009","unstructured":"Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21:117\u201328.","journal-title":"Behav Neurol"},{"key":"500_CR58","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","volume":"132","author":"CR Jack Jr","year":"2009","unstructured":"Jack Jr CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: implications for sequence of pathological events in Alzheimer\u2019s disease. Brain. 2009;132:1355\u201365.","journal-title":"Brain"},{"key":"500_CR59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/01.wnl.0000324924.91351.7d","volume":"71","author":"JL Whitwell","year":"2008","unstructured":"Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71:743\u20139.","journal-title":"Neurology"},{"key":"500_CR60","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/archneur.1992.00530330070019","volume":"49","author":"PR Hof","year":"1992","unstructured":"Hof PR, Bierer LM, Perl DP, Delacourte A, Buee L, Bouras C, et al. Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile plaques. Arch Neurol. 1992;49:946\u201353.","journal-title":"Arch Neurol"},{"key":"500_CR61","first-page":"190","volume":"18","author":"JG Csernansky","year":"2004","unstructured":"Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, et al. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord. 2004;18:190\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"500_CR62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.neuroimage.2004.12.036","volume":"25","author":"JG Csernansky","year":"2005","unstructured":"Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D, et al. Preclinical detection of Alzheimer\u2019s disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage. 2005;25:783\u201392.","journal-title":"Neuroimage"},{"key":"500_CR63","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0531-5565(02)00141-9","volume":"37","author":"A Delacourte","year":"2002","unstructured":"Delacourte A, Sergeant N, Wattez A, Maurage CA, Lebert F, Pasquier F, et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol. 2002;37:1291\u20136.","journal-title":"Exp Gerontol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-014-0500-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-014-0500-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-014-0500-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T13:06:24Z","timestamp":1650200784000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-014-0500-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,21]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["500"],"URL":"https:\/\/doi.org\/10.1007\/s11910-014-0500-6","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,21]]},"article-number":"500"}}